Biora Therapeutics, Inc.
BIORQ
$0.00
$0.000.00%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 892.00K | 860.00K | 544.00K | 4.00K | 18.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 892.00K | 860.00K | 544.00K | 4.00K | 18.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 892.00K | 860.00K | 544.00K | 4.00K | 18.00K |
| SG&A Expenses | 35.33M | 37.45M | 38.01M | 37.31M | 38.11M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 61.77M | 68.83M | 67.66M | 67.15M | 67.59M |
| Operating Income | -60.87M | -67.97M | -67.12M | -67.14M | -67.58M |
| Income Before Tax | -35.73M | -86.92M | -111.12M | -124.42M | -121.91M |
| Income Tax Expenses | -158.00K | -113.00K | -42.00K | -90.00K | 264.00K |
| Earnings from Continuing Operations | -35.57 | -86.81 | -111.08 | -124.33 | -122.17 |
| Earnings from Discontinued Operations | 4.04M | 219.00K | 219.00K | 219.00K | -253.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -31.54M | -86.59M | -110.86M | -124.12M | -122.42M |
| EBIT | -60.87M | -67.97M | -67.12M | -67.14M | -67.58M |
| EBITDA | -60.42M | -67.50M | -66.59M | -66.58M | -66.98M |
| EPS Basic | -10.87 | -54.72 | -71.20 | -85.66 | -95.88 |
| Normalized Basic EPS | -5.66 | -12.11 | -22.39 | -31.42 | -35.30 |
| EPS Diluted | -13.03 | -56.89 | -71.23 | -85.70 | -95.94 |
| Normalized Diluted EPS | -6.24 | -12.69 | -22.39 | -31.42 | -35.30 |
| Average Basic Shares Outstanding | 12.64M | 10.49M | 8.13M | 6.30M | 4.65M |
| Average Diluted Shares Outstanding | 16.49M | 14.33M | 8.13M | 6.30M | 4.65M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |